REV-ERB agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-31 and is reviewed periodically as new material appears.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
=== Recent developments in non-invasive brain stimulation (TMS / tDCS) === During the past several years, both transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) have experienced significant evidence, regulatory analysis, and clinical implementation. According to a 2024 review by Desarkar et al., the body of research on the therapeutic application of non-invasive brain stimulation is growing and represents advancements in the quality of study, the parameters used in stimulation, and the mechanics of research, and the authors point to the progress of the research. The review also emphasizes limitations and ongoing challenges, including variability in individual response, the need for more standardized dosing protocols, and the importance of precise targeting based on neuroimaging or computational modeling. These findings update earlier assessments that characterized the evidence base as limited or inconsistent, particularly for tDCS, and reflect the increasing rigor of recent randomized and multi-site trials. Combination Therapies Emerging work has explored the joint use of multiple stimulation modalities. A 2024 clinical study by Zhou et al. reported that combined tDCS and repetitive TMS (rTMS) demonstrated promising benefits for insomnia, suggesting potential synergistic effects when protocols are integrated. The given combination is still under research, but it represents a broader tendency toward multimodal stimulation techniques.
At that time, surveys indicated that 50–70% of at-risk individuals would have been interested in receiving testing, but since predictive testing has been offered far fewer choose to be tested. Over 95% of individuals at risk of inheriting HD do not proceed with testing, mostly because it has no treatment. A key issue is the anxiety an individual experiences about not knowing whether they will eventually develop HD, compared to the impact of a positive result. Irrespective of the result, stress levels are lower two years after being tested, but the risk of suicide is increased after a positive test result. Individuals found to have not inherited the disorder may experience survivor guilt about family members who are affected. Other factors taken into account when considering testing include the possibility of discrimination and the implications of a positive result, which usually means a parent has an affected gene and that the individual's siblings will be at risk of inheriting it. In one study, genetic discrimination was found in 46% of individuals at risk for Huntington's disease. It occurred at higher rates within personal relationships than health insurance or employment relations. Genetic counseling in HD can provide information, advice and support for initial decision-making, and then, if chosen, throughout all stages of the testing process. Because of the implications of this test, patients who wish to undergo testing must complete three counseling sessions which provide information about Huntington's.
== External links == "Relaxin Family Peptide Receptors: RXFP3". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Archived from the original on 2016-03-03. Retrieved 2008-12-09. This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Classification and Evolution Regulation, Development, and Molecular Diversity Aquatic Environments and Populations Ecology and Biodiversity Management History of Earth Men, Nature, and Societies, and Prehistory The diffusion departments are:
Sources: en.wikipedia.org
The stage was also an important part of Thomas's life from 1929 to 1934, as an actor, writer, producer and set painter. He took part in productions at Swansea Grammar School, and with the YMCA Junior Players and the Little Theatre, which was based in the Mumbles. It was also a touring company that took part in drama competitions and festivals around South Wales. Between October 1933 and March 1934, for example, Thomas and his fellow actors took part in five productions at the Mumbles theatre, as well as nine touring performances. Thomas continued with acting and production throughout his life, including his time in Laugharne, South Leigh and London (in the theatre and on radio), as well as taking part in nine stage readings of Under Milk Wood. The Shakespearian actor, John Laurie, who had worked with Thomas on both the stage and radio thought that Thomas would "have loved to have been an actor" and, had he chosen to do so, would have been "Our first real poet-dramatist since Shakespeare." Painting the sets at the Little Theatre was just one aspect of the young Thomas's interest in art. His own drawings and paintings hung in his bedroom in Cwmdonkin Drive, and his early letters reveal a broader interest in art and art theory. Thomas saw writing a poem as an act of construction "as a sculptor works at stone," later advising a student "to treat words as a craftsman does his wood or stone...hew, carve, mould, coil, polish and plane them..." Throughout his life, his friends included artists, both in Swansea and in London, as well as in America.
=== Suppression of the pro-Alid groups === Mu'awiya died in 680 and was succeeded by his son Yazid I. Mu'awiya's designation of his son was an unprecedented act and shocked many in the Muslim community, particularly the Arab nobility of Kufa. They long sympathized with Caliph Ali, Mu'awiya's former rival, and Ali's family. One of Ali's sons, Husayn dispatched his cousin Muslim ibn Aqil to Kufa to set the stage for Husayn's accession to the caliphate. Ibn Aqil garnered significant support and was hosted by a prominent pro-Alid nobleman. Ubayd Allah became aware of Ibn Aqil's activities, prompting the latter to launch a premature assault against the governor. Ubayd Allah was holed up in his palace, but thirty men from his shurta (security forces) fended off Ibn Aqil's partisans, while he persuaded many Kufan noblemen to back him against Ibn Aqil, who was abandoned by his supporters and slain on 10 September 680. Husayn had already been en route to Kufa from Medina when he received news of Ibn Aqil's execution. Ubayd Allah was prepared for Husayn's arrival and sent troops to intercept him. They prevented Husayn and his small retinue from reaching the watered areas of the province. The two sides negotiated for weeks, but Ubayd Allah refused Husayn entry into Kufa or return to Arabia while Husayn refused to recognize Yazid's caliphate. In the end, a short battle was fought at Karbala on 10 October 680, in which Husayn and nearly all of his partisans were slain.
== Cause == It is usually caused by the deficiency of the enzyme cystathionine beta synthase, mutations of other related enzymes such as methionine synthase, or the deficiency of folic acid, vitamin B12 and/or pyridoxine (vitamin B6).
Sources: en.wikipedia.org
Cannabis was criminalized in some countries beginning in the 14th century and was illegal in most countries by the middle of the 20th century. The colonial government of Mauritius banned cannabis in 1840 over concerns on its effect on Indian indentured workers; the same occurred in Singapore in 1870. In the United States, the first restrictions on sale of cannabis came in 1906 (in the District of Columbia). Canada criminalized cannabis in The Opium and Narcotic Drug Act, 1923, before any reports of the use of the drug in Canada, but eventually legalized its consumption for recreational and medicinal purposes in 2018. In 1925, a compromise was made at an international conference in Geneva about the Second International Opium Convention that banned exportation of "Indian hemp" to countries that had prohibited its use, and requiring importing countries to issue certificates approving the importation and stating that the shipment was required "exclusively for medical or scientific purposes". It also required parties to "exercise an effective control of such a nature as to prevent the illicit international traffic in Indian hemp and especially in the resin". In the United States in 1937, the Marihuana Tax Act was passed, and prohibited the production of hemp in addition to cannabis.
Osteoarthritis is a type of degenerative joint disease that results from breakdown of joint cartilage and underlying bone. A form of arthritis, it is believed to be the fourth leading cause of disability in the world, with an estimated 240 million people worldwide having activity-limiting osteoarthritis. The most common symptoms are joint pain and stiffness. Usually the symptoms progress slowly over years. Other symptoms may include joint swelling, decreased range of motion, and, when the back is affected, weakness or numbness of the arms and legs. The most commonly involved joints are the two near the ends of the fingers and the joint at the base of the thumbs, the knee and hip joints, and the joints of the neck and lower back. The symptoms can interfere with work and normal daily activities. Unlike some other types of arthritis, only the joints, not internal organs, are affected. Possible causes include previous joint injury, abnormal joint or limb development, and inherited factors. Risk is greater in those who are overweight, have legs of different lengths, or have jobs that result in high levels of joint stress. Osteoarthritis is believed to be caused by mechanical stress on the joint and low grade inflammatory processes. It develops as cartilage is lost and the underlying bone becomes affected. As pain may make it difficult to exercise, muscle loss may occur. Diagnosis is typically based on signs and symptoms, with medical imaging and other tests used to support or rule out other problems.
== Etymology == The generic name Datura is taken from Hindi धतूरा dhatūra "thorn-apple", ultimately from Sanskrit धत्तूर dhattūra "white thorn-apple" (referring to Datura metel of Asia). In the Ayurvedic text Sushruta Samhita, different species of Datura are also referred to as kanaka and unmatta. Dhatura is offered to Lord Shiva in Hinduism. Record of this name in English dates back to 1662. Nathaniel Hawthorne refers to one type in The Scarlet Letter as "apple-Peru". In Mexico, its common name is toloache (also spelled tolguacha), which derives from the Nahuatl tolohuaxihuitl, meaning "the plant with the nodding head" (in reference to the nodding seed capsules of Datura species belonging to section Dutra of the genus). The term "Jimsonweed" is said to come from the American colony Jamestown. In Jamestown datura was common, and was referred to as "Jamestown-Weed" by one Virginian, Robert Beverley Jr. This then turned into the term "Jimsonweed".
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.